UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

Clinical cancer research, 2018-12, Vol.24 (23), p.5841-5849

2018

Volltextzugriff (PDF)

Evaluation of dosing strategy for pembrolizumab for oncology indications

Journal for immunotherapy of cancer, 2017-05, Vol.5 (1), p.43-43, Article 43

2017

Volltextzugriff (PDF)

Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development

Clinical and translational science, 2021-11, Vol.14 (6), p.2348-2359

2021

Volltextzugriff (PDF)

Molnupiravir: Mechanism of action, clinical, and translational science

Clinical and translational science, 2024-02, Vol.17 (2), p.e13732-n/a

2024

Volltextzugriff (PDF)

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2852-2856

2009

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age

Antimicrobial Agents and Chemotherapy, 2009-03, Vol.53 (3), p.869-875

2009

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects

Clinical and translational science, 2019-09, Vol.12 (5), p.545-555

2019

Volltextzugriff (PDF)

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals

CPT: pharmacometrics and systems pharmacology, 2023-12, Vol.12 (12), p.1859-1871

2023

Volltextzugriff (PDF)

Immunogenicity of pembrolizumab in patients with advanced tumors

Journal for immunotherapy of cancer, 2019-08, Vol.7 (1), p.212-212, Article 212

2019

Volltextzugriff (PDF)

Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents

Antimicrobial Agents and Chemotherapy, 2005-11, Vol.49 (11), p.4536-4545

2005

Volltextzugriff (PDF)

Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers

Antimicrobial Agents and Chemotherapy, 2009-04, Vol.53 (4), p.1450-1456

2009

Volltextzugriff (PDF)

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

Antimicrobial Agents and Chemotherapy, 2008-12, Vol.52 (12), p.4228-4232

2008

Volltextzugriff (PDF)

Population Pharmacokinetics and Pharmacodynamics of Caspofungin in Pediatric Patients

Antimicrobial Agents and Chemotherapy, 2011-05, Vol.55 (5), p.2098-2105

2011

Volltextzugriff (PDF)

Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects

Clinical infectious diseases, 2008-07, Vol.47 (1), p.137-140

2008

Volltextzugriff (PDF)

Effects of Omeprazole on Plasma Levels of Raltegravir

Clinical infectious diseases, 2009-02, Vol.48 (4), p.489-492

2009

Volltextzugriff (PDF)

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients

Science translational medicine, 2016-11, Vol.8 (363), p.363ra150

2016

Volltextzugriff (PDF)

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

Antimicrobial Agents and Chemotherapy, 2008-09, Vol.52 (9), p.3253-3258

2008

Volltextzugriff (PDF)

Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir

Antimicrobial Agents and Chemotherapy, 2008-12, Vol.52 (12), p.4338-4343

2008

Volltextzugriff (PDF)

Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men

Antimicrobial Agents and Chemotherapy, 2002-03, Vol.46 (3), p.739-745

2002

Volltextzugriff (PDF)

Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis

British journal of clinical pharmacology, 2019-06, Vol.85 (6), p.1072-1083

2019

Volltextzugriff (PDF)

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

Antimicrobial Agents and Chemotherapy, 2009-07, Vol.53 (7), p.2752-2755

2009

Volltextzugriff (PDF)

Hepatic uptake of the novel antifungal agent caspofungin

Drug metabolism and disposition, 2005-05, Vol.33 (5), p.676-682

2005

Volltextzugriff (PDF)

Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma

Antimicrobial Agents and Chemotherapy, 2004-03, Vol.48 (3), p.815-823

2004

Volltextzugriff (PDF)

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

Antimicrobial Agents and Chemotherapy, 2009-05, Vol.53 (5), p.1747-1752

2009

Volltextzugriff (PDF)

Factors Influencing COVID‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes

Clinical pharmacology and therapeutics, 2023-06, Vol.113 (6), p.1337-1345

2023

Volltextzugriff (PDF)

1 – 25 von 943

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(738)
Mit Volltextzugriff
(732)

Publikationsform

5 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(939)
Französisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Pembrolizumab Exposure-Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

Evaluation of dosing strategy for pembrolizumab for oncology indications

Immune‐viral dynamics modeling for SARS‐CoV‐2 drug development

Molnupiravir: Mechanism of action, clinical, and translational science

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

Pharmacokinetics and Safety of Caspofungin in Neonates and Infants Less than 3 Months of Age

Safety, Tolerability, and Pharmacokinetics of the β‐Site Amyloid Precursor Protein‐Cleaving Enzyme 1 Inhibitor Verubecestat (MK‐8931) in Healthy Elderly Male and Female Subjects

Population pharmacokinetics of molnupiravir in adults with COVID‐19: Lack of clinically important exposure variation across individuals

Immunogenicity of pembrolizumab in patients with advanced tumors

Pharmacokinetics, Safety, and Tolerability of Caspofungin in Children and Adolescents

Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy Subjects

Population Pharmacokinetics and Pharmacodynamics of Caspofungin in Pediatric Patients

Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects

Effects of Omeprazole on Plasma Levels of Raltegravir

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer's disease patients

Lack of a Significant Drug Interaction between Raltegravir and Tenofovir

Minimal Effects of Ritonavir and Efavirenz on the Pharmacokinetics of Raltegravir

Single- and Multiple-Dose Pharmacokinetics of Caspofungin in Healthy Men

Clinical and translational pharmacology of the cathepsin K inhibitor odanacatib studied for osteoporosis

Effect of Tipranavir-Ritonavir on Pharmacokinetics of Raltegravir

Hepatic uptake of the novel antifungal agent caspofungin

Disposition of Caspofungin: Role of Distribution in Determining Pharmacokinetics in Plasma

Lack of a Clinically Important Effect of Moderate Hepatic Insufficiency and Severe Renal Insufficiency on Raltegravir Pharmacokinetics

Factors Influencing COVID‐19 Risk: Insights From Molnupiravir Exposure‐Response Modeling of Clinical Outcomes

Suchergebnisse filtern